All In MedTech

Device Trial Radar · NCT03190369

Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee

A 26-week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of 6 mL of Hylan G-F 20 (Synvisc-One®) in Chinese Patients With Symptomatic Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Mar 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

440

Actual

Start

Aug 21, 2017

Primary completion

Jan 28, 2019

Study completion Jan 28, 2019

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanyNot on our public-company list
Sponsor type
Industry
First posted
Jun 16, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: -To evaluate the efficacy of a single 6-milliliter (mL) intra-articular (IA) injection of Hylan G-F 20 measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numerical Rating Scale (NRS) 3.1 A1 score, in comparison to an IA placebo injection over 26 weeks, in Chinese participants with symptomatic Osteoarthritis (OA) of the knee. Secondary Objectives: * To evaluate the efficacy of a single 6-mL IA injection of Hylan G-F 20 measured by 7-day average score of WOMAC A1 pain sub-score in comparison to an IA placebo injection over 26 weeks. * To evaluate the efficacy of a single 6-mL IA injection of Hylan G-F 20 measured by WOMAC A, patient global assessment (PTGA) and clinical observer global assessment (COGA) in comparison to an IA placebo injection over 26 weeks. * To evaluate the response rate of a single 6-mL IA injection of Hylan G-F 20 in comparison to an IA placebo injection over 26 weeks. Response was defined as WOMAC A1 greater than or equal to (\>=) 2-point improvement from baseline on NRS. * To evaluate the safety of a single 6-mL IA injection of Hylan G-F 20, in comparison to an IA placebo injection over 26 weeks.

Conditions

  • Osteoarthritis

Interventions

  • Hylan G-F 20 (GZ402662/SAR402662)Device

    Pharmaceutical form: Solution for injection Route of administration: Intra articular

  • PlaceboDrug

    Pharmaceutical form: Solution for injection Route of administration: Intra articular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Pain (Walking Pain) Subscale Score Over 26 WeeksTime frame: From Baseline up to Week 26

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 1560001

    Beijing, China

  • Investigational Site Number 1560005

    Beijing, China

  • Investigational Site Number 1560020

    Beijing, China

18 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.